Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Biomarkers, Tumor
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Immunotherapy
Male
Middle Aged
Mutation
Neoplasms
Prospective Studies
Response Evaluation Criteria in Solid Tumors
Survival Analysis

authors with profiles

Hedy Kindler